Baxter International (NYSE:BAX) stock price target increased to $52.00, reported today by Barclays Capital
- Updated: September 15, 2016
Baxter International (NYSE:BAX) had its estimated target price upped to $52 by Barclays Capital in a report announced Thursday September 15 2016. The new target price indicates a possible upside of 0.14% from the company’s most recent stock close price.
Boasting a price of $45.43, Baxter International (NYSE:BAX) traded 0.11% higher on the day. With the last close up 2.20% relative to the 200-day moving average, compared with the S&P 500 which has decreased -0.01% over the same period. The company has recorded a 50-day average of $47.40 and 200-day average of $44.45. Trading volume was was down over the average, with 3,772,242 shares of BAX changing hands under the typical 3,934,810 shares.
With a total market value of $0.0, Baxter International has a 52 week low of $32.18 and a 52 week high of $49.49 with a price-earnings ratio of 5.
Also covering Baxter International’s price target, a total of 11 brokers have reported on BAX. The consensus target stock price is $48.82 with 0 rating the stock a strong buy, three firms rating the company a buy, 11 firms rating the stock a hold, one brokerage rating the company to underperform, and lastly 0 firmsrating the company as sell.
Brief Synopsis About Baxter International (NYSE:BAX)
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, and or irreversible kidney failure and acute kidney injuries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.